Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $75

BioMarin Pharmaceutical Inc. +1.08%

BioMarin Pharmaceutical Inc.

BMRN

55.47

+1.08%

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical (NASDAQ: BMRN) with a Overweight and raises the price target from $70 to $75.